GlassScriptPhysician profile
Arthur J Matzkowitz
NPI 1588636831
$3,809.40
in general payments reported to CMS, 2019-2025
45 companies · $618 in 2025
The $618 reported for 2025 was more than what 75% of Therapeutic Radiology providers received nationally (typical 2025 total: $179).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $247 · 2021: $543 · 2022: $567 · 2023: $721 · 2024: $751 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,090.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $504.48 | 2019-2025 | Piqray, Kisqali |
| Janssen Biotech, INC. | $487.46 | 2020-2025 | Rybrevant, Darzalex, Talvey |
| Bayer Healthcare Pharmaceuticals INC. | $283.67 | 2019-2025 | |
| Seagen INC. | $243.23 | 2019-2023 | Padcev, Tukysa, Tivdak |
| Merck Sharp & Dohme LLC | $229.63 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $163.63 | 2019-2025 | Vyloy, Xtandi, Xospata |
| Abbvie INC. | $150.24 | 2024-2025 | |
| Daiichi Sankyo INC. | $100.64 | 2021-2025 | Enhertu, Datroway |
| Gilead Sciences, INC. | $99.28 | 2019-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $91.05 | 2022-2024 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $86.90 | 2023-2025 | Fruzaqla, Alunbrig |
| Genzyme Corporation | $86.39 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $80.63 | 2021-2024 | Imfinzi, Enhertu |
| Rigel Pharmaceuticals, INC. | $78.56 | 2019-2024 | Rezlidhia, Tavalisse |
| Taiho Oncology, INC. | $61.87 | 2024-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $56.87 | 2021-2023 | Ayvakit |
| Sumitomo Pharma America, INC. | $55.57 | 2023-2025 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $54.49 | 2021-2023 | Fotivda |
| Incyte Corporation | $54.20 | 2022-2024 | Jakafi |
| Eisai INC. | $52.40 | 2019-2022 | |
| Lilly USA, LLC | $51.50 | 2022-2023 | Verzenio, Retevmo, Jaypirca |
| Glaxosmithkline, LLC. | $50.50 | 2021-2025 | Jemperli, Zejula |
| Jazz Pharmaceuticals INC. | $50.05 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $49.97 | 2025 | |
| Foundation Medicine, INC. | $47.85 | 2020 | |
| Pfizer INC. | $46.71 | 2022-2024 | |
| Amgen INC. | $45.18 | 2019-2021 | |
| Genentech USA, INC. | $43.42 | 2024 | Polivy, Tecentriq, Tecentriq Hybreza |
| Celgene Corporation | $34.02 | 2024 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $33.28 | 2021-2023 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $30.44 | 2019 | |
| Ge Healthcare | $30.09 | 2022 | |
| Tersera Therapeutics LLC | $28.84 | 2019 | |
| Kyowa Kirin, INC. | $26.99 | 2021 | |
| Puma Biotechnology, INC. | $26.96 | 2021-2022 | |
| Mirati Therapeutics, INC. | $26.41 | 2024 | Krazati |
| Deciphera Pharmaceuticals INC. | $25.13 | 2025 | Romvimza, Qinlock |
| Ipsen Biopharmaceuticals, INC | $22.19 | 2023 | Somatuline Depot, Onivyde |
| Csl Behring | $20.46 | 2021 | |
| Beigene USA, INC. | $18.68 | 2023 | Brukinsa |
| Ethicon US, LLC | $17.81 | 2019 | |
| Emd Serono, INC. | $17.35 | 2025 | |
| Morphosys, US INC. | $16.32 | 2022 | |
| G1 Therapeutics, INC. | $15.26 | 2022 | |
| Karyopharm Therapeutics INC. | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Matzkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.